1. Stroke

2. Schizophrenia

DW1006 is a schizophrenia drug candidate with superior efficacy and minimized side effects. It is now examined in preclinical trials designed to confirm efficacy and safety. Phase I clinical trial is ready for IND submission.

Our areas of interest include anticancer, antibiotics, metabolic diseases and multifaceted conditions. We remain committed to developing original drugs such as new chemical entity, natural products medicines and incrementally modified drugs.